SCHEMBL6487974

SCHEMBL6487974

CCOC(=O)c1cccc(NCc2cc(C)c3nc(C)n(Cc4ccc(Cl)cc4Cl)c3c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 2/20 0.42
PPARA Q07869 1/20 0.42
NAMPT P43490 1/20 0.40
PPARG P37231 1/20 0.40
THRB P10828 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CCKBR P32239 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TSHR P16473 1/20 0.38
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489284 0.90 PPARA (0.50) MAPTPPARAPPARGKMT2AMEN1
SCHEMBL6501460 0.83 LMNA (0.41) MAPTTP53SMN1; SMN2LMNAPPARA
SCHEMBL6488419 0.82 LMNA (0.49) MAPTSMN1; SMN2LMNAPPARGNPC1
SCHEMBL6490180 0.81 LMNA (0.41) SMN1; SMN2LMNAPPARGKDM4EKMT2A
SCHEMBL6489915 0.80 NR4A2 (0.46) MAPTSMN1; SMN2LMNAPPARGNPC1
SCHEMBL6491218 0.77 CD38 (0.44) SMN1; SMN2LMNAPPARGNPSR1ALDH1A1
SCHEMBL6501562 0.77 NR4A2 (0.57) PPARGNPC1RAB9A
SCHEMBL6171804 0.76 DCTPP1 (0.49) MAPTTP53SMN1; SMN2LMNAPPARG
SCHEMBL6490528 0.76 DCTPP1 (0.42) SMN1; SMN2LMNAPPARGALDH1A1
SCHEMBL6490261 0.76 CYP1A2 (0.42) SMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAPT 3168/4885TP53 1741/4885SMN1; SMN2 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.